Last reviewed · How we verify
Hylenex
At a glance
| Generic name | Hylenex |
|---|---|
| Also known as | hyaluronidase human injection, Hylenex (R) recombinant, Hyaluronidase |
| Sponsor | Vanderbilt University Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Peripheral Modulation of Muscle Stiffness and Spasticity (PHASE2)
- dMAbs for Prevention of COVID-19 (PHASE1)
- Hyaluronidase Effect on Infusion Set Life (PHASE1)
- Hylenex-Assisted Resuscitation in Kenya (HARK) Trial for the Management of Dehydration (PHASE2)
- Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase (PHASE4)
- Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20 (PHASE1)
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus (PHASE2)
- Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |